Growth Hormone Axis Research
Peptides targeting the somatotropic axis: GHRHs, GHRPs, and IGF-1 analogs for growth hormone pathway research.
- Compounds
- 13
- Purity
- Verified by HPLC and MS-UPLC on every batch
- Certificate
- Batch-specific COA on every product
About Growth Hormone Axis Research
This category covers compounds studied along the hypothalamic-pituitary somatotropic pathway, from GH-releasing signals through to the downstream IGF-1 response. CJC-1295 and Sermorelin act as GHRH receptor agonists, prompting the anterior pituitary to release growth hormone directly, while Ipamorelin and GHRP-6 work through the separate ghrelin receptor to produce a pulsatile GH spike, with Ipamorelin specifically researched for minimal effect on cortisol and prolactin relative to older GHRPs. IGF-1 LR3 extends the pathway a step further: a recombinant analog engineered with an N-terminal substitution that resists IGFBP binding, giving researchers a longer-acting tool for in vitro IGF-1 signaling work.
>99%
>99%
>99%
>99%
>99%
>99%
>99%
>99%
>99%
>99%
>99%
>99%
>99%Reading on Growth Hormone Axis Research
Evidence reviews and handling references for each compound in this category, kept off the product pages so neither the evidence nor the handling detail is cut short.
CJC-1295 (No DAC)
CJC-1295 With DAC
GHRP-2
GHRP-6
Hexarelin
Ipamorelin
Sermorelin
Tesamorelin
Fragment 176-191
IGF-1 DES
IGF-1 LR3
MGF (Mechano Growth Factor)
From the blog
Background and context on these compounds.
For in-vitro research use only. Not for human or veterinary use.